Tag: Prometic


Canada’s Prometic On Track to Start Phase 2 IPF Study

Prometic Life Sciences announced that its orphan drug PBI-4050 was issued a Promising Innovative Medicine (PIM) designation by the United Kingdom Medicines and Healthcare Products Regulatory Agency as add-on treatment to nintedanib for patients with idiopathic pulmonary fibrosis (IPF).

Read More